Progresses in treating agitation: A major clinical challenge in Alzheimers disease

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 17, 2015, Pages 2581-2588

  Panza, Francesco ^a,b   Solfrizzi, Vincenzo ^a   Seripa, Davide ^b   Imbimbo, Bruno P ^c   Santamato, Andrea ^d   Lozupone, Madia ^a   Prete, Camilla ^e   Greco, Antonio ^b   Pilotto, Alberto ^e   Logroscino, Giancarlo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e GALLIERA HOSPITAL   (Italy)

Author keywords

aggression; agitation; Alzheimer's disease; antidepressants; antipsychotics; brexpiprazole; cannabinoids; citalopram; dementia; dextromethorphan quinidine; dronabinol; mibampator; neuropsychiatric symptoms; prazosin; risperidone; scyllo inositol; selective serotonin reuptake inhibitors: treatment

Indexed keywords

CANNABINOID; CITALOPRAM; DEXTROMETHORPHAN PLUS QUINIDINE; MIBAMPATOR; NEUROLEPTIC AGENT;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; COHEN MANSFIELD AGITATION INVENTORY; CONCEPTUAL FRAMEWORK; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISRUPTIVE BEHAVIOR; EMOTIONAL STRESS; FRONTOTEMPORAL DEMENTIA; IRRITABILITY; MULTIINFARCT DEMENTIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SECONDARY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); DRUG REPOSITIONING; HUMAN; OFF LABEL DRUG USE; PSYCHOLOGY; PSYCHOMOTOR AGITATION;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG REPOSITIONING; HUMANS; OFF-LABEL USE; PSYCHOMOTOR AGITATION;

EID: 84951906409     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1092520     Document Type: Review

References (54)

1. Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric Syndromes Professional Interest Area of ISTAART. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement 2013;9:602-8
2. Panza F, Frisardi V, Seripa D, et al. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. Ageing Res Rev 2012;11:87-103
3. Taragano FE, Allegri RF, Krupitzki H, et al. Mild behavioral impairment. J Clin Psychiatry 2009;70:584-92
4. Ismail Z, Smith EE, Geda Y, et al. ISTAART Neuropsychiatric Symptoms Professional Interest Area. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 2015. [Epub ahead of print]
5. Soto M, Andrieu S, Nourhashemi F, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr 2015;27:181-97
6. Jeste DV, Meeks TW, Kim DS, Zubenko GS. Research agenda for DSM-V: diagnostic categories and criteria for neuropsychiatric syndromes in dementia. J Geriatr Psychiatry Neurol 2006;19:160-71
7. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review and critique. Am J Geriatr Psychiatry 2001;9:361-81
8. Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr 2015;27:7-17
9. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
10. Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord 2007;24:457-63
11. Gallagher D, Herrmann N. Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care. Neurodegener Dis Manag 2015;5:77-83
12. Nowrangi MA, Lyketsos CG, Rosenberg PB. Principles and management of neuropsychiatric symptoms in Alzheimer's dementia. Alzheimers Res Ther 2015;7:12
13. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-16
14. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-19
15. Howard R, Mcshane R, Lindesay J, et al. Donepezil and memantine for moderatetosevere Alzheimer's disease. N Engl J Med 2012;366:893-903
16. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005;330:874-7
17. Howard RJ, Juszczak E, Ballard C, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1382-92
18. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009;21:813-24
19. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404
20. Freund-Levi Y, Jedenius E, Tysen-Bäckström AC, et al. Galantamine versus Risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. Am J Geriatr Psychiatry 2014;22:341-8
21. Freund-Levi Y, Bloniecki V, Auestad B, et al. Galantamine versus Risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dement Geriatr Cogn Disord 2014;38:234-44
22. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-69
23. Schneider LS, Dagerman K, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210
24. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43
25. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103
26. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41
27. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007;164:1568-76
28. Barak Y, Baruch Y, Mazeh D, et al. Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. Am J Geriatr Psychiatry 2007;15:354-6
29. Raivio MM, Laurila JV, Strandberg TE, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a 2-year prospective study. Am J Geriatr Psychiatry 2007;15:416-24
30. Ballard C, Hanney ML, Theodoulou M, et al. DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009;8:151-7
31. Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012;367:1497-507
32. Lopez OL, Becker JT, Chang YF, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 2013;170:1051-8
33. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012;308:2020-9
34. Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Advances in the treatment of agitation in Alzheimer's disease. Exp Opin Pharmacother 2015;16:1649-56
35. Eikelenboom P, Hoogendijk WJ, Jonker C, van Tilburg W. Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. J Psychiatr Res 2002;36:269-80
36. Holmgren S, Hjorth E, Schultzberg M, et al. Neuropsychiatric symptoms in dementia-a role for neuroinflammation? Brain Res Bull 2014;108:88-93
37. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulated cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355-61
38. Bloniecki V, Aarsland D, Cummings J, et al. Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. Dement Geriatr Cogn Dis Extra 2014;4:335-43
39. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA 2014;311:682-91
40. Drye LT, Spragg D, Devanand DP, et al. CitAD Research Group. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One 2014;9:e98426
41. Cummings J, Lyketsos C, Tariot P, et al. Dextromethorphan/Quinidine (AVP-923) efficacy and safety for treatment of agitation in persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440) (S16.007). Neurology 2015;84(14 Suppl):S16.007
42. Chappell AS, Gonzales C, Williams J, et al. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007;68:1008-12
43. Trzepacz PT, Cummings J, Konechnik T, et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr 2013;25:707-19
44. van den Elsen GA, Ahmed AI, Verkes RJ, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology 2015;84:2338-46
45. Walther S, Schüpbach B, Seifritz E, et al. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol 2011;31:256-8
46. Woodward MR, Harper DG, Stolyar A, et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry 2014;22:415-19
47. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonindopamine activity modulator. J Pharmacol Exp Ther 2014;350:589-604
48. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015;164:127-35
49. Lyketsos CG, Colenda CC, Beck C, et al. Task Force of American Association for Geriatric Psychiatry. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006;14:561-72
50. Rabins PV, Blacker D, Rovner BV, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 2007;164(12 Suppl):5-56
51. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010;22:346-72
52. Kales HC, Gitlin LN, Lyketsos CG; Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc 2014;62:762-9
53. Livingston G, Kelly L, Lewis-Holmes E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess 2014;18:1-226
54. Panza F, Solfrizzi V, Imbimbo BP, Logroscino G. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? Expert Opin Biol Ther 2014;14:1465-76